Literature DB >> 16603851

Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.

Shayne Loubser1, Peter Balfe, Gayle Sherman, Scott Hammer, Louise Kuhn, Lynn Morris.   

Abstract

OBJECTIVES: Single-dose nevirapine (sd-NVP) for prevention of mother-to-child HIV-1 transmission is associated with selection of resistant viral variants, particularly the Lysine (K) to Asparagine (N) mutation at codon 103 (K103N) of reverse transcriptase. As this may influence subsequent treatment responses, a better understanding of the dynamics of decay and persistence of this variant is needed. DESIGN AND METHODS: We measured the frequency of K103N mutants among a cohort of HIV-1-infected pregnant women recruited at an out-patient clinic in Johannesburg, South Africa. Samples taken 6 weeks, 3, 7 and 12 months after delivery from 67 HIV-1-infected women who received sd-NVP during labor to prevent transmission were analyzed. Quantification of K103N mutants in maternal plasma viral RNA and cellular DNA was done using an allele-specific real-time polymerase chain reaction assay capable of detecting codons AAC and AAT if their frequency was > 0.002 of the total viral population.
RESULTS: Using the allele-specific assay, 87.1% (27/31) of RNA samples and 52.3% (23/44) of DNA samples collected 6 weeks after sd-NVP had detectable K103N variants. This declined to 65.4% (17/26), 38.9% (14/36), and 11.3% (6/53) in RNA at 3, 7 and 12 months respectively, and to 4.2% (2/48) in DNA at 12 months.
CONCLUSIONS: K103N resistant variants were present in almost all women at 6 weeks post-sd-NVP but declined rapidly over time. Resistant variants were detected less frequently in cellular DNA with persistence in this compartment by 12 months post-sd-NVP among only a minority.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603851      PMCID: PMC2841686          DOI: 10.1097/01.aids.0000222071.60620.1d

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.

Authors:  Monica Nolan; Mary Glenn Fowler; Lynne M Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-06-01       Impact factor: 3.731

Review 2.  HIV-1 drug resistance and mother-to-child transmission.

Authors:  L Morris; C Pillay; G Gray; J McIntyre
Journal:  SADJ       Date:  2001-12

3.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.

Authors:  L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

5.  Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.

Authors:  Jeffrey A Johnson; Jin-Fen Li; Lynn Morris; Neil Martinson; Glenda Gray; James McIntyre; Walid Heneine
Journal:  J Infect Dis       Date:  2005-06-01       Impact factor: 5.226

6.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

7.  Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

Authors:  Coleen K Cunningham; Marie-Laure Chaix; Claire Rekacewicz; Paula Britto; Christine Rouzioux; Richard D Gelber; Alejandro Dorenbaum; Jean Francois Delfraissy; Brigitte Bazin; Lynne Mofenson; John L Sullivan
Journal:  J Infect Dis       Date:  2002-06-26       Impact factor: 5.226

8.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Authors:  J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.

Authors:  Jennifer A Collins; M Gregory Thompson; Elijah Paintsil; Melisa Ricketts; Joanna Gedzior; Louis Alexander
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  45 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

Authors:  Russell B Van Dyke; Nicole Ngo-Giang-Huong; David E Shapiro; Lisa Frenkel; Paula Britto; Anuvat Roongpisuthipong; Ingrid A Beck; Praparb Yuthavisuthi; Sinart Prommas; Thanyawee Puthanakit; Jullapong Achalapong; Nantasak Chotivanich; Wirawan Rasri; Tim R Cressey; Robert Maupin; Mark Mirochnick; Gonzague Jourdain
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

Review 3.  Primary drug resistance in South Africa: data from 10 years of surveys.

Authors:  Justen Manasa; David Katzenstein; Sharon Cassol; Marie-Louise Newell; Tulio de Oliveira
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-12       Impact factor: 2.205

Review 4.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

5.  Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.

Authors:  Christopher F Rowley; Christian L Boutwell; Esther J Lee; Iain J MacLeod; Heather J Ribaudo; M Essex; Shahin Lockman
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

6.  Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Authors:  Roger Paredes; Vincent C Marconi; Thomas B Campbell; Daniel R Kuritzkes
Journal:  J Virol Methods       Date:  2007-07-26       Impact factor: 2.014

7.  Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.

Authors:  Christopher F Rowley; Christian L Boutwell; Shahin Lockman; M Essex
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

8.  High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali.

Authors:  Claudia S Crowell; Almoustapha I Maiga; Mariam Sylla; Babafemi Taiwo; Niaboula Kone; Assaf P Oron; Robert L Murphy; Anne-Geneviève Marcelin; Ban Traore; Djeneba B Fofana; Gilles Peytavin; Ellen G Chadwick
Journal:  Pediatr Infect Dis J       Date:  2017-11       Impact factor: 2.129

9.  Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.

Authors:  Xierong Wei; Gillian Hunt; Salim S Abdool Karim; Vivek Naranbhai; Sengeziwe Sibeko; Quarraisha Abdool Karim; Jin-Fen Li; Angela D M Kashuba; Lise Werner; Jo-Ann S Passmore; Lynn Morris; Walid Heneine; Jeffrey A Johnson
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

10.  Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.

Authors:  Jan Walter; Louise Kuhn; Chipepo Kankasa; Katherine Semrau; Moses Sinkala; Donald M Thea; Grace M Aldrovandi
Journal:  BMC Infect Dis       Date:  2008-12-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.